Show simple item record

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

dc.contributor.authorSolomon, B
dc.contributor.authorMok, T
dc.contributor.authorKim, D
dc.contributor.authorWu, Y
dc.contributor.authorNakagawa, K
dc.contributor.authorMekhail, T
dc.contributor.authorFelip, E
dc.contributor.authorCappuzzo, F
dc.contributor.authorPaolini, J
dc.contributor.authorUsari, T
dc.contributor.authorIyer, S
dc.contributor.authorReisman, A
dc.contributor.authorWilner, K
dc.contributor.authorTursi, J
dc.contributor.authorBlackhall, Fiona H
dc.date.accessioned2015-01-22T15:29:40Z
dc.date.available2015-01-22T15:29:40Z
dc.date.issued2014-12-04
dc.identifier.citationFirst-line crizotinib versus chemotherapy in ALK-positive lung cancer. 2014, 371 (23):2167-77 N Engl J Meden
dc.identifier.issn1533-4406
dc.identifier.pmid25470694
dc.identifier.doi10.1056/NEJMoa1408440
dc.identifier.urihttp://hdl.handle.net/10541/338690
dc.description.abstractThe efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.
dc.language.isoenen
dc.rightsArchived with thanks to The New England journal of medicineen
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCarboplatin
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCisplatin
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshGlutamates
dc.subject.meshGuanine
dc.subject.meshHumans
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshPyrazoles
dc.subject.meshPyridines
dc.subject.meshReceptor Protein-Tyrosine Kinases
dc.titleFirst-line crizotinib versus chemotherapy in ALK-positive lung cancer.en
dc.typeArticleen
dc.contributor.departmentPeter MacCallum Cancer Centre, Melbourne, VIC, Australiaen
dc.identifier.journalThe New England Journal of Medicineen
html.description.abstractThe efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.


This item appears in the following Collection(s)

Show simple item record